Comparative Effectiveness of Botulinum Toxin Injection for Chronic Shoulder Pain: A Meta-Analysis of Randomized Controlled Trials

Po-Cheng Hsu 1,2, Wei-Ting Wu 1,3, Der-Sheng Han 1,3 and Ke-Vin Chang 1,3,*

1 Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Bei-Hu Branch, Taipei 10845, Taiwan; myronrbman@gmail.com (P.-C.H.);
wwtaustin@yahoo.com.tw (W.-T.W.); dshan1121@yahoo.com (D.-S.H.)
2 Institute of Clinical Medicine, National Yang-Ming University, Taipei 11221, Taiwan
3 Department of Physical Medicine and Rehabilitation, National Taiwan University College of Medicine, Taipei 10048, Taiwan
* Correspondence: kvchang011@gmail.com; Tel.: +886-2-2371-7101

Received: 24 March 2020; Accepted: 10 April 2020; Published: 12 April 2020

Abstract: Botulinum toxin (BoNT) injection is regarded as a promising treatment for musculoskeletal pain. However, its efficacy for treating chronic shoulder pain remains unclear. We investigated the effectiveness of BoNT injections for chronic shoulder pain by conducting a systematic search of electronic databases up to March 2020 for randomized control trials (RCTs) that used BoNT injections for chronic shoulder pain treatment. The primary outcome was the between-group comparison of pain reduction, quantified by the standardized mean difference (SMD). Nine RCTs comprising 666 patients were included and divided into two groups: one group with shoulder joint pain (n = 182) and the other group with shoulder myofascial pain (n = 484). Regarding shoulder joint pain, the efficacy of BoNT injections was similar to that of the reference treatment (SMD: −0.605, 95% confidence level [CI]: −1.242 to 0.032 versus saline; SMD: −0.180, 95% CI: −0.514 to 0.153 versus corticosteroids) at one month post-intervention, and was superior (SMD: −0.648, 95% CI: −0.1071 to −0.225 versus corticosteroids) between one and three months. Likewise, in terms of shoulder myofascial pain, the effectiveness of BoNT injections did not differ from the reference treatment (SMD: −0.212, 95% CI: −0.551 to 0.127 versus saline; SMD: 0.665, 95% CI: −0.260 to 1.590 versus dry needling and SMD: 1.093; 95% CI: 0.128 to 2.058 versus lidocaine) at one month post-intervention, and appeared superior (SMD: −0.314, 95% CI: −0.516 to −0.111 versus saline) between one and three months. Our meta-analysis revealed that BoNT injections could be a safe and effective alternative for patients with chronic shoulder pain.

Keywords: Botulinum toxin; corticosteroid; joint; myofascial pain

Key Contribution: This work provides the most updated evidence of botulinum toxin injections in treating chronic painful shoulders.

1. Introduction

Shoulder pain, a prevalent musculoskeletal disorder, is estimated to affect 16% of the general population [1]. The lifetime prevalence of shoulder pain could be up to 67%, according to a systemic review [2]. Shoulder pain not only decreases work efficiency and life quality, but also leads to an increased economic and medical burden on the whole society [1].

The shoulder is a complicated structure. Rotator cuff tendon disorders and related bursal and joint pathology are the most common causes of shoulder pain. However, myofascial pain,
characterized by the presence of myofascial trigger points (MTrPs), can develop over the shoulder region. Its diagnostic criteria consist of taut bands, hypersensitive spots, and referred pain over the affected area, and MTrPs are usually treated as the therapeutic targets [3].

Injection is an effective treatment for musculoskeletal disorders, and the commonly used injectates include corticosteroids, local anesthetics, hyaluronic acid, and high-concentration dextrose [4–6]. Botulinum toxin (BoNT) has been widely used in managing post-stroke spasticity, hemifacial spasm, and cervical dystonia. An increasing amount of evidence suggests that BoNT not only inhibits acetylcholine release at the neuromuscular junction, but also modulates pain by reducing nociceptive neurotransmitters and neurogenic inflammation [7]. In recent years, BoNT injections have been increasingly used to treat mild musculoskeletal disorders, like tennis elbow, knee osteoarthritis, and refractory joint pain [8–10]. However, its effects remain inconclusive regarding chronic shoulder pain based on available systemic reviews and meta-analyses [11,12]. Wu et al. concluded that BoNT injections were effective in treating shoulder pain compared with placebo injections [12]. However, their meta-analysis included stroke patients with hemiplegic shoulders, so the results might not be well-representative of the general population. Conversely, Ahmed et al. demonstrated that the local anesthetic injections were more effective than BoNT injections [11]. Nevertheless, their patients had heterogeneous symptoms and some of them presented with myofascial pain over all body regions. In this regard, this meta-analysis aimed to clarify whether BoNT injections were effective for the treatment of chronic shoulder pain in the general population through reviewing evidence from randomized controlled trials (RCTs).

2. Results

2.1. Study Identification and Selection

The initial search of the databases yielded 564 studies. After excluding 108 duplicated articles and 439 non-relevant articles by screening titles and abstracts, 19 studies were deemed eligible for subsequent evaluation. Ten were further excluded because four lacked a control group [10,13–15], five targeted myofascial pain in regions other than shoulder areas [16–20], and one used an enriched protocol design to assess the effect of repeated BoNT injections [14] (Figure 1).

![Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the study selection process.](image-url)
The final meta-analysis consisted of seven 2-armed [21–27], one 3-armed [28], and one 4-armed [29] trials. Of the four studies investigating shoulder joint pain, one targeted patients with refractory shoulder pain [27], one targeted those with subacromial bursitis or shoulder impingement syndrome [25], one targeted those with adhesive capsulitis [24], and one was shoulder osteoarthritis [23]. The other five studies focused on patients with myofascial pain syndrome over the shoulder region [21,22,26,28,29]. This final meta-analysis included 666 participants, 62.5% of whom were women.

Regarding the reference treatments in the four studies targeting shoulder joint pain, one employed 0.9% saline injections [27] and three employed corticosteroid injections [23–25]. In terms of the five studies for shoulder myofascial pain, four used 0.9% saline [21,22,26,29] and one employed lidocaine and dry needling in two different arms [28]. The details of included studies are documented in Table 1, and the quality assessments are shown in Figure 2.

Figure 2. Summary graph (A) and table (B) of risk for bias of enrolled studies. Green (+): low risk of bias; red (-): high risk of bias; blank: unclear risk of bias.

The type of BoNT used in the included studies was predominantly BoNT-A; only one study used BoNT-B (Myobloc®, Solstice Neurosciences, Inc., South San Francisco, CA, USA) [25]. Among the studies using BoNT-A, two used Botox® (Allergan, Irvine, CA, USA) [26,27], two used Dysport® (Ipsen Ltd., Ipsen Biopharm Ltd., Wrexham, UK) [21,22,24], and three studies did not specify the injections [23,28,29]. The dosage of BoNT varied across different brands. Regarding shoulder joint pain, the common dosage for injection was 100 U of Botox® (BoNT-A), 200 U of Dysport® (BoNT-A) or 2500 U of Myobloc® (BoNT-B). In terms of shoulder myofascial pain, the dosage for injection per trigger point ranged from 5 to 40 U of BoNT-A. The details of regimens, injection techniques, outcome measurements, and follow-up durations are listed in Table 2.
Table 1. Summary of the retrieved trials investigating botulinum toxin on patients with chronic shoulder pain.

| Study | Diagnosis | Enrolled Sample Number (Male/Female) | Average Age, Years | Pain Duration, Months | Double Blind | Randomization | Allocation Concealment | Funding Source |
|-------|-----------|-------------------------------------|-------------------|----------------------|--------------|---------------|-------------------------|----------------|
| Singh et al. 2009 [27] | Refractory shoulder pain | BoNT-A: 21 (20/1) Saline: 22 (22/0) | BoNT-A: 72.1 ± 1.9 Saline: 70.2 ± 2.6 | BoNT-A: 96 ± 24 Saline: 132 ± 36 | Yes | Random table | Yes | Arthritis Foundation North Central Chapter grant; VA Scholar grant from the Center for Epidemiological and Clinical Research; Minneapolis VA Medical Center. NIH CTSA Award; Allergan Pharmaceuticals, Inc. |
| Lee et al. 2011 [25] | Subacromial bursitis or shoulder impingement syndrome | BoNT-B: 31 (14/17) Steroid: 30 (11/19) | BoNT-B: 57.9 ± 10.1 Steroid: 55.8 ± 9.1 | BoNT-B: 8.2 ± 5.5 Steroid: 8.2 ± 7 | Yes | Unclear | Yes | Wooridul Spine Foundation, Korea |
| Joo et al. 2013 [24] | Adhesive capsulitis | BoNT-A: 15 (9/6) Steroid: 13 (8/5) | BoNT-A: 55.0 ± 9.7 Steroid: 53.3 ± 13.7 | BoNT-A: 8.7 ± 7.2 Steroid: 5.7 ± 1.5 | No | Random table | Unclear | Not mentioned |
| Hashemi et al. 2018 [23] | Shoulder osteoarthritis | 50 (24/26) in total: BoNT-A: 25 Steroid: 25 | Mean age: 56 ± 7.6 in total | >3 in total | Yes | Unclear | Unclear | Not mentioned |
| Kamanli et al. 2005 [28] | Trigger point located at cervical, back, or shoulder muscles | 29 participants (6/23) in total: BoNT-A: 9 Lidocaine: 10 Dry needling: 10 | BoNT-A: 38.3 ± 5.26 Lidocaine: 37.30 ± 9.76 Dry needling: 37.20 ± 8.08 | BoNT-A: 49.20 ± 34.96 Lidocaine: 32.50 ± 21.99 Dry needling: 50.66 ± 19.92 | No | Unclear | Unclear | Not mentioned |
| Study and Year | Condition | Number of Patients | BoNT-A Dose | Baseline VAS | Treatment Effect | Randomization | Randomization Method | Hospital Location |
|----------------|-----------|--------------------|-------------|--------------|-----------------|---------------|----------------------|------------------|
| Ferrante et al. 2005 [29] | Cervicothoracic and shoulder myofascial Pain | 31 (3/28) | BoNT-A 10U/TP: 43.3 ± 10.9 (13/19) | >3 | Yes | Random table | Unclear | Not mentioned |
| Ojala et al. 2006 [26] | Neck-shoulder myofascial pain | 31 (3/28) in total: BoNT-A: 15 | BoNT-A: 44.9 ± 7.6 (Saline: 43.8 ± 8.1) | Yes | Block randomization | Unclear | Kuopio University Hospital, Finland |
| Göbel et al. 2006 [22] | Upper back and/or shoulder myofascial pain syndrome | BoNT-A: 74 (16/61) Saline: 70 (16/54) | BoNT-A: 44 ± 12 (Saline: 45 ± 11) | Yes | Block randomization | Yes | Not mentioned |
| Benecke et al. 2011 [21] | Myofascial pain syndrome affecting cervical muscles of the back and shoulder | BoNT-A: 76 (32/44) Saline: 72 (20/52) | BoNT-A: 48 ± 13 (Saline: 45 ± 10) | Yes | Block randomization | Yes | Ipsen, UK |

BoNT: botulinum toxin.
| Author, Year | Botulinum Toxin Type (Brand) | Dose/Volume * | Reference Treatment | Injection Technique | Outcome Measurement | Follow Up | Adverse Effects |
|--------------|-------------------------------|---------------|---------------------|---------------------|--------------------|-----------|-----------------|
| Singh et al. 2009 [27] | BoNT-A (Botox®),pretreated with 2 mL of 1% lidocaine | 100 U/1 mL | 1 mL of 0.9% saline solution + 2 mL of 1% lidocaine | Landmark guided, posterior approach to glenohumeral joint | VAS; SPADI; ROM (flexion + abduction), short-form McGill Pain Questionnaire; SF-36; proportion of responders | 1 month | BoTN-A: 50 AEs (3 serious AEs: 2 chest pain, 1 scheduled cataract surgery) Placebo: 46 AEs (9 serious AEs: 1 chest pain, 2 atrial fibrillation, 1 small-bowel obstruction, 1 abdominal pain, 1 hematuria, 1 acute renal failure, 1 ear pain and 1 anxiety attack) |
| Lee et al. 2011 [25] | BoNT-B (Myobloc®) | 2500 U/0.5 mL + 0.5% lidocaine 2 mL | Triamcinolone 40 mg + 2 mL of 0.5% lidocaine | Ultrasound-guided subacromial bursa injection | NRS, DASH, Shoulder ROM (abduction) | 1 and 3 months | BoTN-B: 2 AEs (injection site discomfort) Triamcinolone: 3 AEs (injection site discomfort) No serious AEs |
| Joo et al. 2013 [24] | BoNT-A (Dysport®) | 200 U/2 mL | Triamcinolone 20 mg (1 mL) + 1 mL of 0.9% saline solution. | Fluoroscopic guidance, anterior approach to glenohumeral joint | NRS; ROM (active flexion, abduction and passive flexion, abduction, external rotation and internal rotation) | 2, 4 and 8 weeks | BoTN-B: 1 AEs (flu-like symptoms) Triamcinolone: 2 AEs (flu-like symptoms) No serious AEs |
| Hashemi et al. 2018 [23] | BoNT-A (not mentioned) | 100 U/5 mL | Triamcinolone 10 mg (4 mL) + 4 mL of 0.9% saline solution. | Ultrasound-guided glenohumeral joint injection | VAS; ROM (External rotation, internal rotation and abduction) | 2 and 12 weeks | Unclear |
| Kamanli et al. 2005 [28] | BoNT-A (not mentioned) | 10–20 U/1–2 mL (22 injections in 9 patients) | (1) Lidocaine group: 1 mL of 0.5% lidocaine solution (32 injections in 10 patients) (2) Dry needling: empty syringe (33 injections in 10 patients) | Palpation guided trigger point injection | VAS; cervical ROM; Pressure pain threshold; Pain score; Hamilton Anxiety and Depression Inventory; Nottingham Health Profile | 1 month | BoNT-A: 9 AEs (5 fatigue, 3 muscle pain, 1 headache) Lidocaine: 6 AEs (3 coldness and burning sensation, 3 paresthesia) No serious AEs |
| Ferrante et al. 2005 [29] | BoNT-A (not mentioned) | 10 U/0.5 mL, 25 U/0.5 mL and 50 U/0.5 mL depending on different arms; maximum 250 U on one patient | 0.5 mL 0.9% saline | Palpation guided trigger point injection | VAS and sum of pain intensity differences; Rescue medication; Pain pressure threshold; SF-36 | 0, 1, 2, 3, 4, 5, 6, 7, 8, 12 weeks | BoNT-A: 3 AEs (flu-like symptoms) No serious AEs |
| Ojala et al. 2006 [26] | BoNT-A (Botox®) | 5U/0.05 mL (range 15–35 U, mean 28 ± 6 U) | 0.05 mL 0.9% saline | Palpation guided trigger point injection | VAS; Self-assessment of the efficacy; Pressure pain threshold | 4 weeks | BoNT-A: 7 AEs (1 injection site pain, 2 vertigo, 1 sweating, 1 hands fatigue, 2 headache) Saline: 4 AEs (1 injection site pain, 1 vertigo, 1 hands fatigue, 1 eyelids swelling) No serious AEs |

**Table 2.** Summary of intervention details of botulinum toxin injection in the retrieved trials.
| Study                  | BoNT-A (Dysport<sup>®</sup>) | Dose and Volume | Palpation guided | Pain intensity§ | Timepoints | AEs | Summary |
|------------------------|------------------------------|----------------|------------------|-----------------|------------|-----|---------|
| Göbel et al. 2006 [22] | 40 U/0.4 mL (10 trigger points) | 0.4 mL of 0.9% saline solution | Palpation guided | Pain intensity§ | 4, 8, 12 weeks | 31 AEs | BoNT-A: 31 AEs Saline: 11 AEs No serious AEs |
| Benecke et al. 2011 [21] | 40 U/0.4 mL (10 fixed injection sites) | 0.4 mL of 0.9% saline solution | 10 standardized predetermined injection sites in the head, neck, and shoulder. | Pain intensity§ | Global evaluation of treatment | 4, 8, 12 weeks | 33 AEs | BoNT-A: 33 AEs Saline: 29 AEs No serious AEs |

*The information is shown as the dose and volume per site regarding for the treatment of myofascial pain. § Pain intensity and Pain score were four-point scale, while 1 (no pain) to 4 (severe pain) for Pain intensity and 0 (no pain) to 3 (severe pain) for Pain score. Abbreviation: BoNT, Botulinum toxin; VAS, Visual Analogue Scale; NRS, Numeric rating scale; SPADI, Shoulder Pain and Disability Index; ROM, range of motion; SF-36, Short form-36; AE, Adverse event.
2.2. Outcomes

2.2.1. Shoulder Joint Pain

Regarding the visual analogue scale (VAS) at one month after intervention, only one trial compared BoNT injections with saline [27]; the standardized mean difference (SMD) was $-0.605$ (95% CI, $-1.242$ to $0.032$) (Figure 3). The other three trials used corticosteroid injections as comparisons and their summarized SMD was $-0.180$ (95% CI, $-0.514$ to $0.153$; I square < 0.001) [23–25]. None of the aforementioned effect sizes reached statistical significance. In terms of VAS between one and three months after intervention, only the studies comparing corticosteroid injections had available data. The pooled SMD was $-0.648$ (95% CI, $-0.1071$ to $-0.225$), indicating a significantly superior outcome of BoNT than corticosteroids.

![Figure 3. Forest plot of pain reduction from botulinum toxin injection for shoulder joint pain at 1 month and between 1–3 months after injection. VAS, visual analogue scale of pain. The square indicates the point estimate and the rhombus represents the pooled effect size.](image)

2.2.2. Shoulder Myofascial Pain

In a triple-arm trial, the SMDs of the VAS at one month post-intervention were 0.665 (95% CI, $-0.260$ to $1.590$) comparing dry needling, and 1.093 (95% CI, 0.128 to 2.058) comparing lidocaine injections [28] (Figure 4). A 4-armed RCT with 3 different doses of BoNT compared with saline was merged into one group to compare the effects after saline injections [29]. Four studies compared saline injections, and the pooled effect size at one month post-intervention was $-0.212$ (95% CI, $-0.551$ to 0.127; I square: 68.8%) [21,22,26,29]. Regarding the VAS between one and three months, the summarized SMD comparing saline from 3 studies was $-0.314$ (95% CI, $-0.516$ to $-0.111$; I square: 3.3%), showing a significant effect favoring BoNT injections.
2.3. Adverse Events

Among the 9 enrolled studies, 8 trials clearly reported the adverse events [21,22,24–29]. Most documented adverse events related to BoNT injections were of mild to moderate severity, such as temporary muscle pain or soreness after treatments. In one study [27], three cases in the BoNT-A group and nine cases in the reference group reported serious adverse events after injections (Table 2). However, most of the events (e.g., chest pain, atrial fibrillation, abdominal pain) were related to their underlying diseases and not to the BoNT injections.

2.4. Publication Bias

2.4.1. Shoulder Joint Pain

Significant publication bias was detected using the Egger test ($p = 0.03$) regarding the VAS at one month post-injection for myofascial pain. However, there was no significant publication bias between one to three months post-injection. The corresponding funnel plot is shown in Figure S1.

2.4.2. Shoulder Myofascial Pain

The $p$-value of the Egger test for the VAS at one month was 0.047, indicating significant publication bias. No significant publication bias was detected regarding the VAS between one to three months post-injection. The corresponding funnel plot is shown in Figure S2.
3. Discussion

3.1. Summary of the Meta-Analysis

The present meta-analysis included available RCTs to investigate the efficacy of BoNT injections in chronic shoulder pain, revealing that the BoNT injection was similar to the reference treatments regarding short-term effectiveness. Compared with corticosteroid and saline injections, BoNT injections yielded more symptom relief between one to three months following treatment in terms of joint and myofascial pain over the shoulder region.

3.2. Botulinum Toxin (BoNT) Injection in Shoulder Joint Pain

Pain over the shoulder joint is predominantly derived from degeneration and chronic inflammation of the rotator cuff tendons and glenohumeral joint. Corticosteroid injections are widely used in the management of shoulder pain based on its anti-inflammatory potential, and its effectiveness has been proven by several clinical studies [30–33]. On the other hand, animal studies demonstrated that BoNT injections could inhibit release of pain mediators, including glutamate, substance P, and calcitonin gene-related peptides [34–36]. Hence, based on our analysis, inflammatory shoulder pain might be modulated by blocking nociception by injecting BoNT, whose short-term efficacy has been shown to be similar to corticosteroid injections.

However, a significantly better outcome of BoNT injections was observed at the mid-term follow-up, implying a more durable effect of BoNT than corticosteroids. Recurrent pain after corticosteroid injections was common [37,38], although the timing of the recurrence varies with initial clinical manifestation and disease severity [32]. Possible explanations for the lasting effect of pain reduction after BoNT injections include: (1) the duration of action of BoNT was longer than corticosteroids (approximately 3 months vs. 8 weeks) [37,39] and (2) BoNT inhibits not only pain mediators, but also impedes downstream neurogenic inflammation [40,41]. Neurogenic inflammation is a phenomenon of reduced sensory nerve thresholds and increased activation of sensory neurons, induced by excitation of nociceptors following the stimulation of pain mediators [42]. Therefore, pain relief after BoNT injections in chronic shoulder joint pain might be attributed to the interference of afferent pain signals and modulation of neurogenic inflammation, which could not be achieved by the administration of corticosteroids [43].

3.3. BoNT Injection in Shoulder Myofascial Pain

For shoulder myofascial pain, our meta-analysis revealed no significant difference in short-term efficacy between BoNT injections and other comparative treatments, like dry needling and injection of saline and lidocaine. Immediate analgesia after injections on MTrPs can be attributed to the needling effect or temporary analgesia after local anesthetics [44]. Moreover, an injection itself may increase muscle circulation [45], which could be achieved both in the BoNT injections and reference groups. Nevertheless, our results revealed that BoNT injections had better mid-term pain relief than saline injections, possibly resulting from the pharmacological effect of BoNT. Some studies showed that pain from MTrPs was the consequence of dysfunction at the motor endplates with subsequent chronic muscle contraction [46]. Administration of BoNT on MTrPs has been shown to reduce acetylcholine release at the neuromuscular junction possible relief of myofascial pain after muscle relaxation. Moreover, the accumulation of oxidative stress and the depletion of the energy supply in MTrPs can reinforce peripheral sensitization of nociception, leading to centralization of pain perception [47]. BoNT injections may inhibit pain mediators released peripherally to decrease central sensitization. Importantly, the average duration of action of BoNT is 12 weeks [48], which also explained why BoNT injections had a longer effect on shoulder myofascial pain than saline injections.

3.4. Type and Dosage of BoNT for Injection

Among all the enrolled studies, only one trial used BoNT-B (Myobloc®) [25]. This was probably due to higher post-injection pain, more symptoms of dysautonomia, shorter duration of action, and
an increased incidence of immunogenicity after the administration of BoNT-B. [49,50]. According to previous literature [51,52], the effective dosage of 100 units (U) of Botox® is equivalent to 200–300 U of Dysport® or 5000 U of Myobloc®. After conversion, we found the dosage of BoNT for intra-bursal injections was roughly half of the dosage for intra-articular injections of our included trials.

Regarding shoulder myofascial pain, the total dosage depends on the dose at each injection site and the number of trigger points. The maximum dose allowed for injections on a patient were predesignated in 3 studies [21,22,26], which was up to 35 U of Botox® [26] and 400 U of Dysport® [21,22]. Caution should be taken regarding the upper limit of BoNT administered per patient, especially for those with preexisting neuromuscular diseases.

3.5. Clinical Implications

This meta-analysis is in favor of BoNT injections for the treatment of chronic shoulder pain. Regarding shoulder joint pain, intra-articular or intra-bursal administration of BoNT has a similar short-term, but better mid-term analgesic effect, compared with corticosteroid injections. In terms of shoulder myofascial pain, BoNT injections could achieve longer lasting pain relief than saline injections.

3.6. Limitations

This meta-analysis has limitations. First, the patients in the enrolled studies had different etiologies. Therefore, we separated them into two groups for analysis based on their causes of pain. Second, the available follow-up durations of all included trials were only up to three months, so the long-term effects of BoNT injections for chronic shoulder pain is unknown. Third, whether BoNT injections could improve shoulder function was not within the scope of this meta-analysis; future studies are needed to explore these questions. Lastly, the number of the studies eligible for inclusion was relatively small when limiting the research type only in RCTs. This might mitigate the power of the conclusion derived from the present meta-analysis. Nevertheless, some case series investigating BoNT injections also demonstrated pain reduction and functional improvement in shoulder joint and myofascial pain [13,53], which were compatible with our findings.

4. Conclusions

BoNT injections had similar short-term efficacy as the reference treatments like corticosteroid and saline injections for relieving chronic shoulder pain. Its effect was superior to the reference treatments between one to three months following injections. The majority of adverse effects pertinent to BoNT injections were temporary and reversible and their severity was mild to moderate. Intra-articular, -bursal, and -muscular administration of BoNT is considered to be a safe and effective alternative for patients with chronic painful shoulders.

5. Methods

5.1. Search Strategy and Criteria

Two electronic databases, PubMed and Embase, were scrutinized for relevant articles published from the earliest record to Jan 2020. We also searched the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov database for suitable references. Moreover, we manually examined the reference lists of the included articles for pertinent trials. The key terms, “botulinum toxin”, “shoulder”, and “myofascial pain” were entered as the medical subject heading and text words for literature searches. The search strategy is presented in Appendix A. The current meta-analysis was not conducted based on any registered or published protocols.
5.2. Inclusion and Exclusion Criteria

The inclusion criteria were as follows: (1) RCTs, (2) enrollment of patients with shoulder pain, including tendon and joint related disorders (including adhesive capsulitis, subacromial impingement and osteoarthritis) and myofascial pain syndrome [54], and (3) quantitative measurements of pain before and after treatments. Furthermore, studies investigating myofascial pain, but not covering the shoulder region, and those recruiting stroke patients with hemiplegic shoulders were not included. Animal studies, case reports, case series, single-arm longitudinal follow-up studies, and quasi-experimental comparative studies were excluded from the present meta-analysis.

5.3. Data Collection and Abstraction

Two authors (P.-C.H. and W.-T.W.) independently screened and evaluated whether the retrieved articles were eligible and met the criteria of inclusion. The information of patient demographics (age, gender ratio, disease duration and type, regimen and site for injection, and the parameters of outcome measurements) were recorded by both authors concurrently using the predesignated evaluation form. The corresponding authors would confirm the correctness of the retrieved data.

5.4. Assessment of Study Quality

The methodological quality of the enrolled studies was assessed using the Cochrane Risk of Bias Tool for RCTs [55]. The risk of bias was classified as either high, low, or unclear. The quality assessment was based on the following aspects: sequence generation (selection bias), allocation concealment (selection bias), blinding of patients and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective outcome reporting (reporting bias). Any discrepancy in opinions of assessments between the two evaluators were solved either through discussion or by the judgment of the corresponding author.

5.5. Meta-Analysis Methodology

The change in the VAS of pain before and after treatment was treated as the primary outcome. The VAS was extracted at or closest to the following points: baseline, within one month and between one to three months after the intervention. The summarized SMD of the VAS changes between two treatment arms was used to compare the effectiveness of BoNT injections with other injectates or approaches [56].

The random effects model was applied for pooling of the effect sizes due to the variations in study designs (such as drug dosage, injection technique, and injection numbers) across the included trials. An SMD of 0.2, 0.5, and 0.8 is considered a small, moderate, and large effect size, respectively [57]. The I-square and Cochran’s Q statistics were used to evaluate the degree of heterogeneity among studies. An I-square value of 25%, 50%, and 75% was considered low, moderate, and high heterogeneity, respectively [58]. The symmetry of the effect size distribution on the funnel plot and the result from the Egger’s test were used to assess the potential publication bias. All the analyses were conducted using Comprehensive Meta-analysis Software version 3 (Biostat, Englewood, NJ, USA), and \( p < 0.05 \) was considered statistically significant.

Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/12/4/251/s1, Figure S1: Funnel plot for the comparisons of the standardized mean difference at (A) one month and (B) between one and three months after injection for shoulder joint pain, Figure S2: Funnel plot for the comparisons of the standardized mean difference at (A) one month and (B) between one and three months after injection for shoulder myofascial pain.

Author Contributions: Conceptualization, K.-V.C.; methodology, K.-V.C. and P.-C.H.; software, K.-V.C.; validation, K.-V.C. and P.-C.H.; investigation, P.-C.H. and W.-T.W.; writing—original draft preparation, P.-C.H.;
Conflicts of Interest: The authors declare no conflict of interest.

References

1. Urwin, M.; Symmons, D.; Allison, T.; Brammah, T.; Busby, H.; Roxby, M.; Simmons, A.; Williams, G. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalance of symptoms at different anatomical sites, and the relation to social deprivation. *Ann. Rheum. Dis.* 1998, 57, 649–655, doi:10.1136/ard.57.11.649.

2. Luime, J.J.; Koes, B.W.; Hendriksen, I.J.; Burdorf, A.; Verhagen, A.P.; Miedema, H.S.; Verhaar, J.A. Prevalence and incidence of shoulder pain in the general population; a systematic review. *Scand. J. Rheumatol.* 2004, 33, 73–81, doi:10.1080/030097403100046667.

3. Fernandez-de-Las-Penas, C.; Dommerholt, J. International Consensus on Diagnostic Criteria and Clinical Considerations of Myofascial Trigger Points: A Delphi Study. *Pain Med.* 2018, 19, 142–150, doi:10.1093/pm/pnx207.

4. Monseau, A.J.; Nizran, P.S. Common injections in musculoskeletal medicine. *Prim. Care* 2013, 40, 987–1000, ix-x, doi:10.1016/j.pop.2013.08.012.

5. Reeves, K.D.; Sit, R.W.S.; Rabago, D.P. Dextrose Prolotherapy: A Narrative Review of Basic Science, Clinical Research, and Best Treatment Recommendations. *Phys. Med. Rehabil. Clin.* 2016, 27, 783–823, doi:10.1016/j.pmr.2016.06.001.

6. Frizziero, A.; Vittadini, F.; Oliva, F.; Abatangelo, G.; Bacci, S.; Bernardi, A.; Bossa, M.; Buda, R.; Buonocore, D.; Calderazzi, F., et al. I.S.Mu.L.T. Hyaluronic acid injections in musculoskeletal disorders guidelines. *Muscle Ligaments Tendons J.* 2018, 8, 364–398., doi:10.32098/mljt.03.2018.04.

7. Bach-Rojecky, L.; Salkovic-Petrisic, M.; Lackovic, Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. *Eur. J. Pharm.* 2010, 633, 10–14, doi:10.1016/j.ejphar.2010.01.020.

8. Hayton, M.J.; Santini, A.J.; Hughes, P.J.; Frostick, S.P.; Trail, L.A.; Stanley, J.K. Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. *J. Bone Jt. Surg* 2005, 87, 503–507, doi:10.2106/JBJS.D.01896.

9. Boon, A.J.; Smith, J.; Dahm, D.L.; Sorenson, E.J.; Larson, D.R.; Fitz-Gibbon, P.D.; Dykstra, D.D.; Singh, J.A. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. *PM R* 2010, 2, 268–276, doi:10.1016/j.pmrj.2010.02.011.

10. Mahowald, M.L.; Singh, J.A.; Dykstra, D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. *Neurotox. Res.* 2006, 9, 179–188, doi:10.1007/bf03033937.

11. Ahmed, S.; Subramaniam, S.; Sidhu, K.; Khattab, S.; Singh, D.; Babineau, J.; Kumbhare, D.A. Effect of Local Anesthetic Versus Botulinum Toxin-A Injections for Myofascial Pain Disorders: A Systematic Review and Meta-Analysis. *Clin. J. Pain* 2019, 35, 353–367, doi:10.1097/AJP.0000000000000681.

12. Wu, T.; Fu, Y.; Song, H.X.; Ye, Y.; Dong, Y.; Li, J.H. Effectiveness of Botulinum Toxin for Shoulder Pain Treatment: A Systematic Review and Meta-Analysis. *Arch. Phys. Med. Rehabil.* 2015, 96, 2214–2220, doi:10.1016/j.apmr.2015.06.018.

13. Kim, D.Y.; Kim, J.M. Safety and Efficacy of PrabotulinumtoxinA (Nabota(R)) Injection for Cervical and Shoulder Girdle Myofascial Pain Syndrome: A Pilot Study. *Toxins (Basel)* 2018, 10, doi:10.3390/toxins10090305.

14. Nicol, A.L.; Wu, I.I.; Ferrante, F.M. Botulinum toxin type a injections for cervical and shoulder girdle myofascial pain using an enriched protocol design. *Anesth Analg* 2014, 118, 1326–1335, doi:10.1213/ane.0000000000001912.

15. Singh, J.A.; Mahowald, M.L.; Kushnaryov, A.; Goelz, E.; Dykstra, D. Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain. *J. Clin. Rheumatol.* 2009, 15, 35–38, doi:10.1097/RHU.0b013e3181953b14.
16. Kwanichiwa, P.; Petchnumsin, T.; Yiemsiri, P.; Pasuk, N.; Srikanok, W.; Hathaiareurg, C. Efficacy and Safety of Single Botulinum Toxin Type A (Botox(R)) Injection for Relief of Upper Trapezius Myofascial Trigger Point: A Randomized, Double-Blind, Placebo-Controlled Study. J. Med. Assoc. Thai. 2015, 98, 1231–1236.

17. Lew, H.L.; Lee, E.H.; Castaneda, A.; Klima, R.; Date, E. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study. Arch. Phys. Med. Rehabil. 2008, 89, 75–80, doi:10.1016/j.apmr.2007.08.133.

18. Miller, D.; Richardson, D.; Eisa, M.; Bajwa, R.J.; Jabbari, B. Botulinum neurotoxin-A for treatment of refractory neck pain: a randomized, double-blind study. Pain Med. 2009, 10, 1012–1017, doi:10.1111/j.1526-4637.2009.00658.x.

19. Wheeler, A.H.; Goolkasian, P.; Gretz, S.S. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998, 23, 1662–1666, doi:10.1097/00007632-199808100-00009.

20. Wheeler, A.H.; Goolkasian, P.; Gretz, S.S. Botulinum toxin A for the treatment of chronic neck pain. Pain 2001, 94, 255–260, doi:10.1016/s0304-3959(01)00358-x.

21. Benecke, R.; Heizne, A.; Reichel, G.; Hefter, H.; Gobel, H. Dysport myofascial pain study, g. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections? Pain Med. 2011, 12, 1607–1614, doi:10.1111/j.1526-4637.2011.01163.x.

22. Gobel, H.; Heinzle, A.; Reichel, G.; Hefter, H.; Benecke, R. Dysport myofascial pain study, g. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 2006, 125, 82–88, doi:10.1016/j.pain.2006.05.001.

23. Hashemi, S.M.; Khamene, S.M.H.; Naderi-Nabi, B.; Ghasemi, M. Effects of ultrasound-guided intraarticular botox vs. corticosteroids for shoulder osteoarthritis. Anaesth. Pain Intensive Care 2019, 22, 355–360.

24. Joo, Y.J.; Yoon, S.J.; Kim, C.W.; Lee, J.H.; Kim, Y.J.; Koo, J.H.; Song, S.H. A comparison of the short-term effects of a botulinum toxin type a and triamcinolone acetate injection on adhesive capsulitis of the shoulder. Ann. Rehabil. Med. 2013, 37, 208–214, doi:10.5535/arm.2013.37.2.208.

25. Lee, J.H.; Lee, S.H.; Song, S.H. Clinical effectiveness of botulinum toxin type B in the treatment of subacromial bursitis or shoulder impingement syndrome. Clin. J. Pain 2011, 27, 523–528, doi:10.1097/AJP.0b013e3182e1310.

26. Ojala, T.; Arokoski, J.P.; Partanen, J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin. J. Pain 2006, 22, 90–96, doi:10.1097/01.ajp.0000151871.51406.c3.

27. Singh, J.A.; Mahowald, M.L.; Noorbaloochi, S. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl. Res. 2009, 153, 205–216, doi:10.1016/j.trsl.2009.02.004.

28. Kamanli, A.; Kaya, A.; Ardícoglu, O.; Ozgocmen, S.; Zengin, F.O.; Bayik, Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol. Int. 2005, 25, 604–611, doi:10.1007/s00296-004-0485-6.

29. Ferrante, F.M.; Bearl, L.; Rothrock, R.; King, L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005, 103, 377–383, doi:10.1097/00000542-200508000-00021.

30. Buchbinder, R.; Green, S.; Youd, J.M. Corticosteroid injections for shoulder pain. Cochrane Database Syst. Rev. 2003, doi:10.1002/14651858.CD004016.

31. Wu, W.T.; Chang, K.V.; Han, D.S.; Chang, C.H.; Yang, F.S.; Lin, C.P. Effectiveness of Glenohumeral Joint Dilatation for Treatment of Frozen Shoulder: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Sci. Rep. 2017, 7, 10507, doi:10.1038/s41598-017-10895-w.

32. Chang, K.V.; Wu, W.T.; Han, D.S.; Ozczakar, L. Static and Dynamic Shoulder Imaging to Predict Initial Effectiveness and Recurrence After Ultrasound-Guided Subacromial Corticosteroid Injections. Arch. Phys. Med. Rehabil. 2017, 98, 1984–1994, doi:10.1016/j.apmr.2017.01.022.
33. Wang, J.C.; Chang, K.V.; Wu, W.T.; Han, D.S.; Ozczakar, L. Ultrasound-Guided Standard vs Dual-Target Subacromial Corticosteroid Injections for Shoulder Impingement Syndrome: A Randomized Controlled Trial. *Arch. Phys. Med. Rehabil.* **2019**, *100*, 2119–2128, doi:10.1016/j.apmr.2019.04.016.

34. Lucioni, A.; Bales, G.T.; Lotan, T.L.; McGeeh, D.S.; Cook, S.P.; Rapp, D.E. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. *Bjirim* **2008**, *101*, 366–370, doi:10.1111/j.1464-410X.2007.07312.x.

35. Durham, P.L.; Cady, R.; Cady, R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. *Headache* **2004**, *44*, 35–42; discussion 42-33, doi:10.1111/j.1526-4610.2004.04007.x.

36. Meng, J.; Ovsepeian, S.V.; Wang, J.; Pickering, M.; Sasse, A.; Aoki, K.R.; Lawrence, G.W.; Dolly, J.O. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. *J. Neurosci.* **2009**, *29*, 4981–4992, doi:10.1523/JNEUROSCI.5490-08.2009.

37. Gatjouj-Viala, C.; Dougdos, M.; Gossec, L. Efficacy and safety of steroid injections for shoulder and elbow tendonitis: a meta-analysis of randomised controlled trials. *Ann. Rheum. Dis.* **2009**, *68*, 1843–1849, doi:10.1136/ard.2008.095772.

38. Mohamadi, A.; Chan, J.J.; Claessen, F.M.; Ring, D.; Chen, N.C. Corticosteroid Injections Give Small and Transient Pain Relief in Rotator Cuff Tendinosis: A Meta-analysis. *Clin. Orthop. Relat. Res.* **2017**, *475*, 223–242, doi:10.1007/s11999-016-5002-1.

39. Hallett, M. Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them. *Toxicon* **2015**, *107*, 64–67, doi:10.1016/j.toxicon.2015.07.013.

40. Jankovic, J.; Schwartz, K. Botulinum toxin injections for cervical dystonia. *Neurology* **1990**, *40*, 277–280, doi:10.1223/wnl.40.2.277.

41. Gobel, H.; Heinze, A.; Heinze-Kuhn, K.; Jost, W.H. Evidence-based medicine: botulinum toxin A in migraine and tension-type headache. *J. Neurol.* **2001**, *248*, 34–38, doi:10.1007/pl00007818.

42. Gangadharan, V.; Kuner, R. Pain hypersensitivity mechanisms at a glance. *Dis. Models Mech.* **2013**, *6*, 889–895, doi:10.1242/dmm.011502.

43. Freitas, J.O.; Quicergatto, P.R.; Hochman, B.; Lapin, G.A.; Mella, S.M.; Maximino, J.R.; Chadi, G.; Ferreira, L.M. Does dexamethasone act in neuropeptides SP and CGRP in neurogenic inflammation of the skin? An experimental study. *Acta Cir. Bras.* **2015**, *30*, 523–528, doi:10.1590/S0102-86502015008000002.

44. Lewit, K. The needle effect in the relief of myofascial pain. *Pain* **1979**, *6*, 83–90, doi:10.1016/0304-3959(79)90142-8.

45. Cagnie, B.; Barbe, T.; De Riddere, E.; Van Oosterwijck, J.; Cools, A.; Danneels, L. The influence of dry needling of the trapezius muscle on muscle blood flow and oxygenation. *J. Manip. Physiol.* **2012**, *35*, 685–691, doi:10.1016/j.jmpls.2012.10.005.

46. Simons, D.G.; Hong, C.Z.; Simons, L.S. Endplate potentials are common to midfiber myofacial trigger points. *Am. J. Phys. Med. Rehabil.* **2002**, *81*, 212–222, doi:10.1097/00002060-200203000-00010.

47. Fricton, J. Myofascial Pain: Mechanisms to Management. *Oral Maxillofac. Surg. Clin.* **2016**, *28*, 289–311, doi:10.1016/j.coms.2016.03.010.

48. Fonfría, E.; Maignel, J.; Lezmi, S.; Martin, V.; Splevins, A.; Shubber, S.; Kalinichev, M.; Foster, K.; Picaut, P.; Krupp, J.; et al. The Expanding Therapeutic Utility of Botulinum Neurotoxins. *Toxins (Basel)* **2018**, *10*, doi:10.3390/toxins10050208.

49. Bentivoglio, A.R.; Del Grande, A.; Petracca, M.; Ialongo, T.; Ricciardi, L. Clinical differences between botulinum neurotoxin type A and B. *Toxicon* **2015**, *107*, 77–84, doi:10.1016/j.toxicon.2015.08.001.

50. Woodruff, B.A.; Griffin, P.M.; McCroskey, L.M.; Smart, J.F.; Wainwright, R.B.; Bryant, R.G.; Hutwagner, L.C.; Hatheway, C.L. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975–1988. *J. Infect. Dis.* **1992**, *166*, 1281–1286, doi:10.1093/infdis/166.6.1281.

51. Blitzer, A. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. *Otolaryngol. Head Neck Surg.* **2005**, *133*, 836–838, doi:10.1016/j.otohns.2005.09.008.

52. Scaglione, F. Conversion Ratio between Botox(R), Dysport(R), and Xeomin(R) in Clinical Practice. *Toxins (Basel)* **2016**, *8*, doi:10.3390/toxins8030065.
53. Cinone, N.; Letizia, S.; Santoro, L.; Gravina, M.; Amoruso, L.; Molteni, F.; Ranieri, M.; Santamato, A. Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature. *J. Pain Res.* 2018, 11, 1239–1245, doi:10.2147/JPR.S159700.

54. Mysiew, W.J.; Colachis, S.C., 3rd. The pronator syndrome. An evaluation of dynamic maneuvers for improving electrodiagnostic sensitivity. *Am. J. Phys. Med. Rehabil.* 1991, 70, 274–277.

55. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. *Bmj* 2003, 327, 557–560, doi:10.1136/bmj.327.7414.

56. Higgins, J.P.; Altman, D.G.; Gotzsche, P.C.; Juni, P.; Moher, D.; Oxman, A.D.; Savovic, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A., et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *Bmj* 2011, 343, d5928, doi:10.1136/bmj.d5928.

57. Chang, K.V.; Wu, W.T.; Hung, C.Y.; Han, D.S.; Yang, R.S.; Chang, C.H.; Lin, C.P. Comparative Effectiveness of Suprascapular Nerve Block in the Relief of Acute Post-Operative Shoulder Pain: A Systematic Review and Meta-analysis. *Pain Physician* 2016, 19, 445–456.

58. Lipsey, M.W.; Wilson, D.B. Practical meta-analysis; Sage Publications, Inc: Thousand Oaks, CA, US, 2001; pp. ix, 247.